Next Article in Journal
An Expanded Interplay Network between NF-κB p65 (RelA) and E2F1 Transcription Factors: Roles in Physiology and Pathology
Previous Article in Journal
Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study
Previous Article in Special Issue
External Validation of a Prognostic Score for Survival in Lung Carcinoids
 
 
Review
Peer-Review Record

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

Cancers 2022, 14(20), 5046; https://doi.org/10.3390/cancers14205046
by Melania Grottoli 1,†, Paolo Carrega 2,†, Lodovica Zullo 3, Chiara Dellepiane 3, Giovanni Rossi 3, Francesca Parisi 3, Giulia Barletta 3, Linda Zinoli 4, Simona Coco 5, Angela Alama 5, Silvia Marconi 5, Monica Parodi 1, Paola Orecchia 1, Sara Bassi 1, Massimo Vitale 1, Maria Cristina Mingari 1,6, Ulrich Pfeffer 7, Carlo Genova 4,8,*,‡ and Gabriella Pietra 1,6,*,‡
Reviewer 1: Anonymous
Reviewer 2:
Reviewer 3:
Cancers 2022, 14(20), 5046; https://doi.org/10.3390/cancers14205046
Submission received: 14 September 2022 / Revised: 9 October 2022 / Accepted: 12 October 2022 / Published: 14 October 2022

Round 1

Reviewer 1 Report

This review article provides an overview about the exploration of NK cells in immune checkpoint blockage therapy for cancer treatment. Authors described the significance of NK cells, their associated mechanism in immune checkpoint inhibitors in very well manner, more specifically in terms of clinical efficacy.

Before publication the manuscript requires some suggestions to improve the overall concept:

1. Introduction part must be improved in terms of incorporation of more content related to immunotherapy and immune checkpoint. Authors can refer to the latest article in this field:

https://doi.org/10.3390/ph15030335

https://doi.org/10.2174/1871520620666200728121929

2. Authors must include a figure to represent the section 5/6.

3. Authors have described the therapeutics used for the anticancer therapy in both the sections (section 5 and 6), if possible try to present under a common heading/subheading.

4. Typographical errors are present at several places throughout the manuscript. Authors must proofread the whole manuscript for possible errors. For example,

Line number: 118 …….”in vivo [19]”

Line number 165 ….. [33] [34],

Line number 202……. tumor progression[47]

Line number 260…… (NCT04513……..

5. Authors must used full form for abbreviation wherever used first time.

6. Conclusion section should be improved in terms of future perspectives.

Author Response

First of all we want to thank the review since her/his advices have been found very useful in order to improve our manuscript. All the modifications made to the paper in order to follow the suggestions are written in red.

Point by point reply:

  1. Introduction part must be improved in terms of incorporation of more content related to immunotherapy and immune checkpoint. Authors can refer to the latest article in this field: R: As suggested by the assessor we have improved the introduction part and the latest articles in the field, have been quoted.
  2. Authors must include a figure to represent the section 5/6. R: As suggested, we have included a figure to represent section 5.
  3. Authors have described the therapeutics used for the anticancer therapy in both the sections (section 5 and 6), if possible try to present under a common heading/subheading. R: Both sections are now under a common heading.
  4. Typographical errors are present at several places throughout the manuscript. Authors must proofread the whole manuscript for possible errors. R: We have carefully proofread the manuscript for typo errors.
  5. Authors must use full form for abbreviation wherever used first time. R: We have used the full form name when used for the first time
  6. Conclusion section should be improved in terms of future perspectives. R: The conclusion section has been implemented as suggested

Reviewer 2 Report

The review by Melania Grottoli et al. titled “Immune checkpoint blockade: a strategy to unleash the potential of Natural Killer cells in the anti-cancer therapy.” provides an overview of the recent findings concerning the role of classical and non-classical immune checkpoint molecules and receptors that regulate natural killer cell function. The review is well-written and pleasant reading. It focuses on the rationale, mechanisms of action, and clinical efficacy of the NK cell-based checkpoint blockade therapy. The topic is certainly timely, with many important discoveries on this topic made in the past few years. Also, the topic should interest a large number of scientists interested in the efficacy of ICB. The authors reviewed the recent literature well and summarized the key findings. Despite a couple of minor points (see below), this reviewer support publication of the manuscript once those few points are solved.:

 

Some punctuation marks need to be checked. Line 217, 268, 355. Full stops are missing.

Line 343. This reference “Barry K C Nat Med 2018 PMID: 29942093” is the same that 77

 

Author Response

First of all, we want to thank the review for her/his kindness and comments.

As recommended by the assessor we have carefully proofread the manuscript for typo errors.

Reviewer 3 Report

The work is great, but, there are so many abbreviations. I would recommend the authors to either provide full forms of the abbreviations initially at their first mention or to include a table with all the abbreviations and their respective full forms. 

There are many strong statements that were made that had either 1 or no citations whatsoever. 

Comments for author File: Comments.pdf

Author Response

First of all we want to thank the review since her/his advices have been found very useful in order to improve our manuscript. The modifications made to the paper in order to follow the suggestions are written in green.

We have provided in the text the full forms of the abbreviations at their first mention. The have revised the text following the suggestions found in the attached PDF file (peer-review-22774097.v1.pdf)

Round 2

Reviewer 3 Report

all good. No further revisions

Back to TopTop